These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 39193150)

  • 1. Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO).
    Lee ST; Abboud H; Irani SR; Nakajima H; Piquet AL; Pittock SJ; Yeh EA; Wang J; Rajan S; Overell J; Smith J; St Lambert J; El-Khairi M; Gafarova M; Gelfand JM
    Front Neurol; 2024; 15():1437913. PubMed ID: 39193150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.
    Bennett JL; Fujihara K; Kim HJ; Marignier R; O'Connor KC; Sergott RC; Traboulsee A; Wiendl H; Wuerfel J; Zamvil SS; Anania VG; Buffels R; Künzel T; Lekkerkerker AN; Lennon-Chrimes S; Pittock SJ
    Front Neurol; 2023; 14():1114667. PubMed ID: 36873431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody induced seizure susceptibility and impaired cognitive performance in a passive transfer rat model of autoimmune encephalitis.
    Pişkin ŞA; Korkmaz HY; Ulusoy CA; Şanlı E; Küçükali CI; Onat F; Tüzün E; Çarçak N
    Front Immunol; 2023; 14():1268986. PubMed ID: 38035091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
    N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Fung S; Shirley M
    CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
    Traboulsee A; Greenberg BM; Bennett JL; Szczechowski L; Fox E; Shkrobot S; Yamamura T; Terada Y; Kawata Y; Wright P; Gianella-Borradori A; Garren H; Weinshenker BG
    Lancet Neurol; 2020 May; 19(5):402-412. PubMed ID: 32333898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis.
    Dürr M; Nissen G; Sühs KW; Schwenkenbecher P; Geis C; Ringelstein M; Hartung HP; Friese MA; Kaufmann M; Malter MP; Madlener M; Thaler FS; Kümpfel T; Senel M; Häusler MG; Schneider H; Bergh FT; Kellinghaus C; Zettl UK; Wandinger KP; Melzer N; Gross CC; Lange P; Dreyhaupt J; Tumani H; Leypoldt F; Lewerenz J;
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34697224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis.
    Wickel J; Chung HY; Platzer S; Lehmann T; Prüss H; Leypoldt F; Günther A; Scherag A; Geis C;
    Trials; 2020 Jul; 21(1):625. PubMed ID: 32641101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABA
    Rada A; Hagemann A; Aaberg Poulsen C; Baumgartner T; Berki T; Blaabjerg M; Brenner J; Britton JW; Christiana A; Ciano-Petersen NL; Crijnen Y; Elišák M; Farina A; Friedman AR; Hayden Z; Hébert J; Holtkamp M; Hong Z; Honnorat J; Ilyas-Feldmann M; Irani SR; Kovac S; Marusic P; Muñiz-Castrillo S; Ramanathan S; Smith KM; Steriade C; Strippel C; Surges R; Titulaer MJ; Uy CE; de Vries JM; Bien CG; Specht U
    Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200225. PubMed ID: 38838283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
    Kleiter I; Traboulsee A; Palace J; Yamamura T; Fujihara K; Saiz A; Javed A; Mayes D; Büdingen HV; Klingelschmitt G; Stokmaier D; Bennett JL
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36724181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy.
    Dubey D; Britton J; McKeon A; Gadoth A; Zekeridou A; Lopez Chiriboga SA; Devine M; Cerhan JH; Dunlay K; Sagen J; Ramberger M; Waters P; Irani SR; Pittock SJ
    Ann Neurol; 2020 Feb; 87(2):313-323. PubMed ID: 31782181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
    Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
    Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective Observational Study of Autoimmune Encephalitis in Northwestern India.
    Sharma B; Paul M; Bagaria AK
    J Assoc Physicians India; 2023 Sep; 71(9):39-44. PubMed ID: 38700300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series.
    Yamamura T; Araki M; Fujihara K; Okuno T; Misu T; Guo YC; Hemingway C; Matsushima J; Sugaya N; Yamashita M; von Büdingen HC; Miyamoto K
    Mult Scler Relat Disord; 2022 May; 61():103772. PubMed ID: 35537314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seizure Semiology in Antibody-Associated Autoimmune Encephalitis.
    Kaaden T; Madlener M; Angstwurm K; Bien CG; Bogarin Y; Doppler K; Finke A; Gerner ST; Reimann G; Häusler M; Handreka R; Hellwig K; Kaufmann M; Kellinghaus C; Koertvelyessy P; Kraft A; Lewerenz J; Menge T; Paliantonis A; von Podewils F; Prüss H; Rauer S; Ringelstein M; Rostásy K; Schirotzek I; Schwabe J; Sokolowski P; Suesse M; Sühs KW; Surges R; Tauber SC; Thaler F; Bergh FT; Urbanek C; Wandinger KP; Wildemann B; Mues S; Zettl U; Leypoldt F; Melzer N; Geis C; Malter M; Kunze A;
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36266054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry.
    Thaler FS; Zimmermann L; Kammermeier S; Strippel C; Ringelstein M; Kraft A; Sühs KW; Wickel J; Geis C; Markewitz R; Urbanek C; Sommer C; Doppler K; Penner L; Lewerenz J; Rößling R; Finke C; Prüss H; Melzer N; Wandinger KP; Leypoldt F; Kümpfel T;
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34599001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF-Neurofilament Light Chain Levels in NMDAR and LGI1 Encephalitis: A National Cohort Study.
    Nissen MS; Ryding M; Nilsson AC; Madsen JS; Olsen DA; Halekoh U; Lydolph M; Illes Z; Blaabjerg M
    Front Immunol; 2021; 12():719432. PubMed ID: 34975832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rare case of anti-LGI1 limbic encephalitis with concomitant positive NMDAR antibodies.
    Ji T; Huang Z; Lian Y; Wang C; Zhang Q; Li J
    BMC Neurol; 2020 Sep; 20(1):336. PubMed ID: 32894089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurological syndromes and potential triggers associated with antibodies to neuronal surface antigens.
    Klein da Costa B; de Oliveira Pinto P; Staub L; Hansel G; Vanik Pinto G; Porcello Schilling L; Rodrigues Dos Passos G; Alves Martins W; Becker J; Machado Castilhos R; Palmini A; Sato DK
    Mult Scler Relat Disord; 2023 Dec; 80():105022. PubMed ID: 37864878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.